Has Prakash Gudsoorkar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,115 in general payments to Prakash Gudsoorkar, MD across 41 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Prakash Gudsoorkar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Prakash Gudsoorkar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Prakash Gudsoorkar, MD

Nephrology · Cincinnati, OHNPI 1417458175

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Akebia Therapeutics Inc accounts for 64.4% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $7,307, more than ten times the $229 reported in 2019. Among nephrology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,115in general payments, 2019–2025

Across 41 payments — averaging $246.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Akebia Therapeutics Inc$7K
CSL Behring$1K
Amgen$653
AstraZeneca$286
Vifor Pharma, Inc.$271
Sanofi$132
plus $911 from 10 others

$114,324in research payments, 2019–2025

Across 9 payments — averaging $12,703 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Vertex$84K
AstraZeneca$30K

What the payments were for

Consulting fees$601%
Speaking & faculty fees$5,51354%
Travel & lodging$1,92619%
Food & beverage$2,61726%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Akebia Therapeutics Inc	9	$6,518
CSL Behring	4	$1,344
Amgen	6	$653
AstraZeneca(2 entities)	5	$286
Vifor Pharma, Inc.	2	$271
Sanofi	1	$132
Nxstage Medical, Inc.	2	$132
Novartis	1	$127
Bayer	3	$126
Fresenius USA Marketing, Inc.	1	$107
Outset Medical Inc	2	$100
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$97
Travere Therapeutics, Inc.	1	$75
GSK	1	$60
Vertex	1	$49
Aurinia Pharma U.S., Inc.	1	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,115 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio →

Medicare billing

Part B allowed, 2024

$68,081

Medicare patients

194

Services billed

709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	13	$15,231
VeltassaPatiromer Calcium Sorbitex	11	$7,451
Clonidine	22	$2,257
Calcium Acetate	32	$1,922
Nifedipine ErNifedipine	62	$1,411
Sevelamer Carbonate	12	$1,170
Torsemide	23	$426
Amlodipine Besylate	36	$190
Lisinopril	31	$166
Carvedilol	24	$159
Clonidine Hcl	18	$129
Losartan Potassium	18	$124
Labetalol Hcl	11	$112
Spironolactone	13	$106
Rosuvastatin Calcium	12	$31

Paid to pharmacies, not to this prescriber.

Other nephrology in Cincinnati

Amit GovilCincinnati$298K
Prabir Roy ChaudhuryCincinnati$205K
Charuhas ThakarCincinnati$107K
Chebel KhalilCincinnati$72K
Arshdeep TindniCincinnati$41K
Joseph KremerCincinnati$29K
Tahir SajjadCincinnati$20K
Silvi ShahCincinnati$14K
Ahmad AnjakCincinnati$9K
Karl PembaurCincinnati$7K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →